Product Description
Besipirdine was designed to address two biochemical deficits commonly observed in the AD brain: cholinergic and adrenergic activity. This drug has been shown to enhance the activity of both systems (Sourced from: https://www.alzforum.org/therapeutics/besipirdine-hcl)
Mechanisms of Action: HTR6 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: INSTITUT DE RECHERCHE PIERRE FABRE
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Urinary Incontinence, Stress
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2009-014049-10 |
2009-014049-10 | P2 |
Completed |
Urinary Incontinence, Stress |
2010-07-12 |
2022-03-13 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|